238 related articles for article (PubMed ID: 28700424)
1. Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.
Chen X; Arend R; Hamele-Bena D; Tergas AI; Hawver M; Tong GX; Wright TC; Wright JD
Int J Gynecol Pathol; 2017 Sep; 36(5):412-419. PubMed ID: 28700424
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
Pinto A; Mackrides N; Nadji M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):393-397. PubMed ID: 27801734
[TBL] [Abstract][Full Text] [Related]
3. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics.
Kernochan LE; Garcia RL
J Natl Compr Canc Netw; 2009 May; 7(5):550-6; quiz 557. PubMed ID: 19460280
[TBL] [Abstract][Full Text] [Related]
4. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
5. PAX8 expression in uterine malignant mesodermal mixed tumor (carcinosarcoma).
Holmes BJ; Gown AM; Vang R; Ronnett BM; Yemelyanova A
Int J Gynecol Pathol; 2014 Jul; 33(4):425-31. PubMed ID: 24901404
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of EZH2, p16 and p53 expression in uterine carcinosarcomas.
Makk E; Bohonyi N; Oszter A; Éles K; Tornóczky T; Tóth A; Kálmán E; Kovács K
Pathol Oncol Res; 2023; 29():1611547. PubMed ID: 38146588
[No Abstract] [Full Text] [Related]
7. Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors.
Buza N; Tavassoli FA
Int J Gynecol Pathol; 2009 Nov; 28(6):514-21. PubMed ID: 19851197
[TBL] [Abstract][Full Text] [Related]
8. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components.
Kounelis S; Jones MW; Papadaki H; Bakker A; Swalsky P; Finkelstein SD
Hum Pathol; 1998 Jan; 29(1):82-7. PubMed ID: 9445138
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component.
de Jong RA; Nijman HW; Wijbrandi TF; Reyners AK; Boezen HM; Hollema H
Mod Pathol; 2011 Oct; 24(10):1368-79. PubMed ID: 21572397
[TBL] [Abstract][Full Text] [Related]
10. Uterine Carcinosarcomas - Diagnosis and Management.
Denschlag D; Ulrich UA
Oncol Res Treat; 2018; 41(11):675-679. PubMed ID: 30317231
[TBL] [Abstract][Full Text] [Related]
11. The immunohistochemical profile of malignant mixed müllerian tumor. Overlap with endometrial adenocarcinoma.
Meis JM; Lawrence WD
Am J Clin Pathol; 1990 Jul; 94(1):1-7. PubMed ID: 1694389
[TBL] [Abstract][Full Text] [Related]
12. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
13. Pathology of mixed Müllerian tumours.
D'Angelo E; Prat J
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):705-18. PubMed ID: 21742560
[TBL] [Abstract][Full Text] [Related]
14. [Sarcomas and mixed mesodermal tumors of the uterus].
Günthert AR
Ther Umsch; 2011 Oct; 68(10):559-64. PubMed ID: 21968895
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas.
Seidman JD; Chauhan S
Int J Gynecol Pathol; 2003 Jan; 22(1):75-82. PubMed ID: 12496702
[TBL] [Abstract][Full Text] [Related]
16. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases.
Jones TE; Pradhan D; Dabbs DJ; Bhargava R; Onisko A; Jones MW
Int J Gynecol Pathol; 2021 Jan; 40(1):84-93. PubMed ID: 31855950
[TBL] [Abstract][Full Text] [Related]
18. p53 immunostaining suggests that uterine carcinosarcomas are monoclonal.
Mayall F; Rutty K; Campbell F; Goddard H
Histopathology; 1994 Mar; 24(3):211-4. PubMed ID: 8200622
[TBL] [Abstract][Full Text] [Related]
19. Eight cases of malignant mixed Müllerian tumor (carcinosarcoma) of the uterus: findings in SurePath™ cervical cytology.
Gupta N; Dudding N; Smith JH
Diagn Cytopathol; 2014 Feb; 42(2):165-9. PubMed ID: 22865798
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report.
Semczuk A; Skomra D; Chyzyńska M; Szewczuk W; Olcha P; Korobowicz E
Pathol Res Pract; 2008; 204(3):203-7. PubMed ID: 18207653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
